Related references
Note: Only part of the references are listed.Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden
Johanna Svensson et al.
SCANDINAVIAN JOURNAL OF UROLOGY (2021)
Prevalence of Prostate Cancer at Different Clinical Stages in Italy: Estimated Burden of Disease Based on a Modelling Study
Federico Spandonaro et al.
BIOLOGY-BASEL (2021)
Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population
Bingcao Wu et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Cora N. Sternberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C. Parker et al.
ANNALS OF ONCOLOGY (2020)
Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer
Stephen J. Freedland et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Managing Nonmetastatic Castration-resistant Prostate Cancer
Joaquin Mateo et al.
EUROPEAN UROLOGY (2019)
Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction
John Esther et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
E. J. Small et al.
ANNALS OF ONCOLOGY (2019)
Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015
Farhad Pishgar et al.
JOURNAL OF UROLOGY (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Experiences of Structured Elicitation for Model-Based Cost-Effectiveness Analyses
Marta O. Soares et al.
VALUE IN HEALTH (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
Dragan Ilic et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Expert Elicitation: Using the Classical Model to Validate Experts' Judgments
Abigail R. Colson et al.
REVIEW OF ENVIRONMENTAL ECONOMICS AND POLICY (2018)
Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location
Harold Evelyn Taitt
AMERICAN JOURNAL OF MENS HEALTH (2018)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2017)
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Wanling Xie et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Androgen Signaling in Prostate Cancer
Charles Dai et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
EXPLICIT: a feasibility study of remote expert elicitation in health technology assessment
Bogdan Grigore et al.
BMC MEDICAL INFORMATICS AND DECISION MAKING (2017)
A comparison of two methods for expert elicitation in health technology assessments
Bogdan Grigore et al.
BMC MEDICAL RESEARCH METHODOLOGY (2016)
Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?
Daniel M. Geynisman et al.
EUROPEAN UROLOGY (2016)
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer
Candice Yong et al.
CURRENT OPINION IN ONCOLOGY (2014)
Cost-of-illness studies: concepts, scopes, and methods
Changik Jo
CLINICAL AND MOLECULAR HEPATOLOGY (2014)
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
T. Karantanos et al.
ONCOGENE (2013)
Eliciting expert opinion for economic models: An applied example
Jose Leal et al.
VALUE IN HEALTH (2007)
Overconfidence in interval estimates
JB Soll et al.
JOURNAL OF EXPERIMENTAL PSYCHOLOGY-LEARNING MEMORY AND COGNITION (2004)
Economic note - Cost of illness studies
S Byford et al.
BRITISH MEDICAL JOURNAL (2000)
Share Paper
